Pay in 4 interest-free payments of $5.38 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
GLP-1-based therapies for type 2 diabetes: from single, dual and triple agonists to endogenous GLP-1 production and L-cell differentiation
Although there are no specific trials of these standard care medications in HFmrEF, analysis of trials that included people with HFmrEF did indicate that their benefits also extended to this population (NICE, 2023)
For patients who arent candidates for surgery or prefer a non-invasive approach, GLP-1 therapy offers a powerful alternative
Stick around as we answer your pressing questions, debunk the myths, and uncover the science-backed reality
Epub 2011 Mar 15
US$ 22.38
US$ 25.16
US$ 25.12
US$ 24.59
US$ 22.84
